A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
Abroad (travel likely)Recruiting
Conditions
Dermatitis Atopic
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Investigational Site Number: 002, Bologna, Italy
Investigational Site Number: 006, Brescia, Italy
Investigational Site Number: 004, Florence, Italy
Investigational Site Number: 001, Milan, Italy
Investigational Site Number: 010, Naples, Italy
Investigational Site Number: 011, Naples, Italy
Investigational Site Number: 005, Roma, Italy
Investigational Site Number: 009, Roma, Italy
Investigational Site Number: 014, Verona, Italy
Study leads
Clinical Sciences & Operations
Study Director
Sanofi